Immunic's Vidofludimus Calcium Achieves Major Milestones in Reducing Disability in MS Patients

Immunic's Breakthrough in Multiple Sclerosis Treatment



Immunic, Inc. recently revealed significant findings from its Phase 2 CALLIPER trial, which assessed the efficacy of its investigational drug, Vidofludimus Calcium (IMU-838), in patients suffering from Primary Progressive Multiple Sclerosis (PPMS). This study marks a pivotal moment in the battle against MS, particularly for those who have limited treatment options.

In the trial involving 467 patients, it was observed that Vidofludimus Calcium reduced the risk of confirmed disability worsening by 30% in the PPMS subgroup. Such a decrease is remarkable considering that this population typically experiences relentless progression without relapses. Furthermore, across the entire study population, there was a 20% reduction in 24-week confirmed disability worsening events compared to the placebo group.

The CALLIPER trial was designed as an international, multicenter, randomized, double-blind, placebo-controlled study with the goal of establishing the clinical efficacy, safety, and tolerability of Vidofludimus Calcium. It enrolled participants from over 70 sites across North America and Europe, ensuring a diverse representation of MS patients. Each participant was administered either Vidofludimus Calcium or a placebo for a maximum duration of 120 weeks.

Efficacy and Safety Findings


One of the most compelling aspects of this trial was the consistent reduction in disability worsening across various patient subpopulations. Notably, those without gadolinium-enhancing lesions saw a 29% reduction in confirmed disability worsening events. This outcome is particularly pertinent as patients exhibiting such lesions typically do not benefit from current anti-inflammatory therapies. Thus, the results imply that Vidofludimus Calcium may provide a new therapeutic avenue for these difficult cases.

In addition to disability progression, the trial also explored neurological outcomes via MRI assessments. The drug notably halted the annualized rate of thalamic brain volume loss by 20% compared to placebo. Thalamic atrophy has been linked to severe disability progression in MS patients, making these results highly significant for clinical practice.

Immunic's CEO, Daniel Vitt, expressed excitement over these findings, emphasizing that the trial's results support the advancement of Vidofludimus Calcium to a Phase 3 registration trial. He highlighted the groundbreaking nature of the 30% reduction in disability progression among PPMS patients, signaling hope for those who live with this challenging disease.

The Calliper study’s findings also uphold Vidofludimus Calcium's previously noted safety and tolerability profile. No significant new safety signals emerged, and the rates of treatment-emergent adverse events were comparable between those taking the drug and the placebo group.

Implications for Multiple Sclerosis


Multiple Sclerosis remains an unpredictable and often debilitating disorder, characterized by the immune system attacking the protective covering of nerves. This disease commonly leads to a reduction in mobility and quality of life for those affected. The findings from the CALLIPER trial highlight the urgent need for new therapeutic mechanisms, especially for progressive forms of MS, which are significantly underserved by current treatment options.

With only one existing treatment approved for PPMS, the potential of Vidofludimus Calcium as a pioneering neuroprotective therapeutic could fill an essential gap. As the demand for effective and safe treatments continues to grow, Immunic’s innovative work could bring new hope to MS patients seeking relief from their symptoms and a better quality of life.

In summary, the CALLIPER trial demonstrates that Vidofludimus Calcium not only significantly reduces the risk of disability worsening in PPMS but also showcases a favorable safety profile, positioning it as a promising candidate for future clinical use. Immunic's commitment to advancing MS treatments could rewrite the narrative for patients struggling with this challenging disease. The ongoing conversations with healthcare authorities will determine the next steps for bringing this potential game-changer to the market, aiming for completion of Phase 3 trials by 2026. If successful, Vidofludimus Calcium could be a landmark advancement in the therapeutic landscape of Multiple Sclerosis.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.